CAS Ion Completes RMB 600 Million First-Round Financing, Fusion-Derived Technology Industrialization Enters a New Stage

Recently, CAS Ion completed its first round of market-oriented equity financing, with a total amount of RMB 600 million. This round of financing was jointly participated in by CMBI, Wanneng Capital, Qianhai Ark, CITIC Construction Investment Capital, China-Belgium Fund, SMIC Juyuan, Oriental Fortune Capital, Xi'an High-Tech Investment, Ginkgo Valley Capital, Jinju Investment, Wofu Venture Capital, and Hua'an Jiaye.

CAS Ion, in accordance with its own business development pace, coordinated and determined the scale of this round of fundraising, and completed all processes including project matching, due diligence interviews, agreement signing, and capital delivery within 3 months. This financing received an enthusiastic market response, with numerous investment institutions actively expressing investment intentions, fully confirming the capital market's high recognition of the company's core technology, industrialization capability, and long-term growth value. The funds raised in this round will be primarily directed toward key areas such as continued R&D of core technologies and market expansion. Based on this round's fundraising plan and project implementation schedule, some high-quality investment institutions were unable to participate in this round of investment, and the company stated that it looks forward to continuing to work together in subsequent financing rounds. A decade of deep cultivation, accumulating strength for a great leap forward. Relying on the technological heritage of the Institute of Plasma Physics, Chinese Academy of Sciences, to build a solid foundation for innovation, and with the long-term companionship of patient capital such as Hefei Industrial Investment and Hefei High-Tech Investment, CAS Ion adheres to independent innovation and continues to tackle the industrialization of high-end equipment. The new investors introduced in this round will join hands with existing shareholders to jointly support the company in continuously expanding the industrialization layout of fusion-derived technologies in multiple scenarios including nuclear medicine, nuclear energy, and nuclear instrumentation. Standing at the new starting point of completing its first round of financing, CAS Ion will continue to face the world's frontier of science and technology, face the main battlefield of the economy, face the major needs of the nation, and face the life and health of the people, base itself on its main business of nuclear technology application, build a world-class R&D and manufacturing center for nuclear medicine, nuclear fusion, and nuclear instrumentation, and promote the high-quality development of the fusion-derived technology application industry. About CAS Ion

CAS Ion was established in March 2016. It is a national-level high-tech enterprise established through the commercialization of technological achievements from major scientific facilities of the Hefei Institutes of Physical Science, Chinese Academy of Sciences, and is also an innovation platform of the Hefei Comprehensive National Science Center co-built by the Chinese Academy of Sciences and the People's Government of Anhui Province. The company has achieved industrialization implementation from core components and subsystem integration to complete system delivery. Its independently developed superconducting cyclotron proton radiotherapy system has achieved domestic production and been put into clinical use, and its core component, the SC240 superconducting proton cyclotron, has achieved mass production; the 14 MeV cyclotron has been recognized as the first set of major technical equipment in Anhui Province; nuclear fusion superconducting technology products such as large-bore superconducting magnets have already served the construction of related facilities, forming an independently controllable industrial chain for the application of fusion-derived technologies. As of now, the company has cumulatively obtained nearly 300 authorized patents, led the formulation of 2 international standards, 6 national standards, and more than 40 other standards, and is a benchmark enterprise for the commercialization of achievements at the Hefei Comprehensive National Science Center